Novavax’s COVID-19 vaccine receives approval for adolescents in Asian region

US-based Novavax, Inc., a biotechnology company dedicated to developing and commercialising nextgeneration vaccines for serious infectious diseases, has announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has received expanded manufacturing and marketing approval from Japan, expanded emergency use authorisation in Thailand, post approval change application by South Korea, provisional registration in Australia, and expanded provisional approval in New Zealand, for primary immunisation to prevent COVID-19) in adolescents aged 12 through 17. The company has also filed for expanded emergency use authorisation in Taiwan. Novavax has partnered with Takeda to develop, manufacture, and distribute Nuvaxovid in Japan, and partnered with SK bioscience to provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea. Novavax has established partnerships for the manufacture, commercialisation and distribution of its COVID-19 vaccine worldwide. Existing authorisations leverage Novavax’s manufacturing partnership with Serum Institute of India, the world’s largest vaccine manufacturer by volume.